Oncotelic

Oncotelic is a biotechnology company focused on developing innovative therapies for cancer and rare diseases. They generate revenue through the research and development of novel drug candidates, often partnering with other pharmaceutical companies for clinical trials and commercialization. Founded in 2015, Oncotelic has made significant strides in immuno-oncology, particularly with their lead drug candidate, OT-101, which targets TGF-β2 for the treatment of various cancers. The company is known for its commitment to advancing precision medicine and improving patient outcomes.

Recent Posts by Oncotelic

1-15 of 15